Approximately one-third of patients with epilepsy presents seizures despite adequate treatment. Hence, there is the need to search for new therapeutic options. Cannabidiol (CBD) is a major chemical component of the resin of Cannabis sativa plant, most commonly known as marijuana. The anti-seizure properties of CBD do not relate to the direct action on cannabinoid receptors, but are mediated by a multitude of mechanisms that include the agonist and antagonist effects on ionic channels, neurotransmitter transporters, and multiple 7-transmembrane receptors. In contrast to tetra-hydrocannabinol, CBD lacks psychoactive properties, does not produce euphoric or intrusive side effects, and is largely devoid of abuse liability.

Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis / Lattanzi, Simona; Brigo, Francesco; Trinka, Eugen; Zaccara, Gaetano; Cagnetti, Claudia; Del Giovane, Cinzia; Silvestrini, Mauro. - In: DRUGS. - ISSN 0012-6667. - STAMPA. - 78:17(2018), pp. 1791-1804. [10.1007/s40265-018-0992-5]

Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis

Lattanzi, Simona
Writing – Review & Editing
;
Cagnetti, Claudia
Investigation
;
Silvestrini, Mauro
Supervision
2018-01-01

Abstract

Approximately one-third of patients with epilepsy presents seizures despite adequate treatment. Hence, there is the need to search for new therapeutic options. Cannabidiol (CBD) is a major chemical component of the resin of Cannabis sativa plant, most commonly known as marijuana. The anti-seizure properties of CBD do not relate to the direct action on cannabinoid receptors, but are mediated by a multitude of mechanisms that include the agonist and antagonist effects on ionic channels, neurotransmitter transporters, and multiple 7-transmembrane receptors. In contrast to tetra-hydrocannabinol, CBD lacks psychoactive properties, does not produce euphoric or intrusive side effects, and is largely devoid of abuse liability.
2018
File in questo prodotto:
File Dimensione Formato  
Drugs 2018.pdf

solo utenti autorizzati

Tipologia: Documento in post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza d'uso: Tutti i diritti riservati
Dimensione 2.08 MB
Formato Adobe PDF
2.08 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/261970
Citazioni
  • ???jsp.display-item.citation.pmc??? 72
  • Scopus 152
  • ???jsp.display-item.citation.isi??? 139
social impact